About AEterna Zentaris (TSE:AEZ)
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:AEZ
CUSIPN/A
Phone+1-843-9003223
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,996.27%
Return on Equity-3,046.52%
Return on Assets-164.23%
Miscellaneous
EmployeesN/A
Outstanding Shares11,671,000
AEterna Zentaris (TSE:AEZ) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AEZ."
When is AEterna Zentaris' next earnings date?
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Carolyn Egbert, Independent Chairman of the Board
- Michael Ward, President, Chief Executive Officer, Director
- James Clavijo, Chief Financial Officer (Age 52)
- Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
- Jude Dinges, Chief Commercial Officer, Senior Vice President (Age 58)
- Eckhard G. Gunther Ph.D., Vice President - Alliance Management
- Michael Teifel, Vice President - Non-Clinical Sciences
- John W. Sharkey Ph.D., Business Development Consultant (Age 60)
- Philip Allen Theodore, Corporate Secretary (Age 64)
- David A. Dodd, Director (Age 65)
Has AEterna Zentaris been receiving favorable news coverage?
News headlines about AEZ stock have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AEterna Zentaris earned a news impact score of 0.14 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of AEterna Zentaris?
Shares of AEZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEZ stock can currently be purchased for approximately C$2.11.
How big of a company is AEterna Zentaris?
AEterna Zentaris has a market capitalization of C$34.20 million.
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 315 Sigma Dr Ste 302D, SUMMERVILLE, SC 29486-7790, United States. The biopharmaceutical company can be reached via phone at +1-843-9003223.
MarketBeat Community Rating for AEterna Zentaris (AEZ)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
AEterna Zentaris (TSE:AEZ) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for AEterna Zentaris in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
AEterna Zentaris (TSE:AEZ) Consensus Price Target History
AEterna Zentaris (TSE:AEZ) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 5/10/2017 | HC Wainwright | Reiterated Rating | Buy | |  |
(Data available from 4/25/2016 forward)
AEterna Zentaris (TSE:AEZ) Earnings History and Estimates Chart
AEterna Zentaris (TSE AEZ) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/14/2018 | | | | | | | | |
| 11/8/2017 | Q3 2017 | C($0.56) | C($0.55) | | C$0.30 million | View | N/A | |
| 8/10/2017 | Q2 2017 | C($0.56) | C($0.61) | C$0.45 million | C$0.33 million | View | N/A | |
| 5/8/2017 | Q1 2017 | | C($0.41) | | C$0.35 million | View | N/A | |
| 3/15/2017 | Q4 2016 | | C($0.95) | | C$0.41 million | View | N/A | |
| 11/8/2016 | Q3 2016 | | C($0.79) | | C$0.35 million | View | N/A | |
| 8/9/2016 | Q2 2016 | | C($0.92) | | C$0.12 million | View | N/A | |
| 5/9/2016 | Q1 2016 | | C($0.51) | | C$0.33 million | View | N/A | |
| 3/29/2016 | Q4 2015 | | C($1.88) | | C$0.13 million | View | N/A | |
| 11/5/2015 | Q3 2015 | | C($9.00) | | C$0.23 million | View | N/A | |
| 8/13/2015 | Q2 2015 | | C($17.00) | | C$0.24 million | View | N/A | |
| 5/7/2015 | Q1 2015 | | C($16.00) | | C$0.09 million | View | N/A | |
| 3/17/2015 | Q4 2014 | | C$8.00 | | C$0.01 million | View | N/A | |
| 11/4/2014 | Q3 2014 | | C($23.00) | | | View | N/A | |
| 8/7/2014 | Q2 2014 | | C($10.00) | | | View | N/A | |
| 5/8/2014 | Q1 2014 | | C($9.00) | | | View | N/A | |
| 3/20/2014 | Q4 2013 | | C($32.00) | | | View | N/A | |
| 11/5/2013 | Q3 2013 | C($27.00) | C$14.00 | C$2.30 million | C$22.03 million | View | N/A | |
| 8/8/2013 | Q2 2013 | C($24.00) | C$37.00 | C$8.53 million | C$31.06 million | View | N/A | |
| 5/7/2013 | 1Q13 | | C$0.07 | C$8.19 million | C$16.73 million | View | N/A | |
| 3/21/2013 | Q4 2012 | C($28.00) | C($30.00) | | | View | N/A | |
| 11/13/2012 | Q3 2012 | C($44.00) | C($35.00) | | | View | N/A | |
| 8/14/2012 | Q2 2012 | C($41.99) | C($33.91) | | | View | N/A | |
| 5/9/2012 | Q1 2012 | C($53.99) | C($64.79) | | | View | N/A | |
| 3/27/2012 | Q4 2011 | C($53.99) | C($41.68) | | | View | N/A | |
| 11/10/2011 | Q3 2011 | C($59.99) | C$6.60 | | | View | N/A | |
| 8/10/2011 | Q2 2011 | C($47.99) | C($70.19) | | | View | N/A | |
| 5/18/2011 | Q1 2011 | C($47.99) | C($58.79) | | | View | N/A | |
| 3/22/2011 | Q4 2010 | C($41.99) | C($17.64) | | | View | N/A | |
| 11/9/2010 | Q3 2010 | C($65.99) | C($73.19) | | | View | N/A | |
| 8/12/2010 | Q2 2010 | C($53.99) | C($37.79) | | | View | N/A | |
| 5/13/2010 | Q1 2010 | C($65.99) | C($56.82) | | | View | N/A | |
| 3/24/2010 | Q4 2009 | | C$118.78 | | | View | N/A | |
| 11/11/2009 | Q3 2009 | C($131.97) | C($122.38) | | | View | N/A | |
| 8/11/2009 | Q2 2009 | C($167.97) | C($158.37) | | | View | N/A | |
| 3/11/2009 | Q4 2008 | | C($208.76) | | | View | N/A | |
| 3/5/2008 | Q4 2007 | | C($152.97) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
AEterna Zentaris (TSE:AEZ) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AEterna Zentaris (TSE AEZ) Insider Trading and Institutional Ownership History
AEterna Zentaris (TSE AEZ) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2016 | David Alan Dodd | Director | Buy | 500 | C$3.06 | C$1,528.50 | | |
| 1/22/2016 | Jude Dinges | Insider | Buy | 6,500 | C$3.07 | C$19,955.00 | | |
| 1/21/2016 | Philip Allen Theodore | Insider | Buy | 6,735 | C$3.00 | C$20,180.08 | | |
(Data available from 1/1/2013 forward)
AEterna Zentaris (TSE AEZ) News Headlines
| Source: |
|
AEterna Zentaris (TSE:AEZ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
AEterna Zentaris (TSE AEZ) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
